Cequent releases primate safety, efficacy data for oral FAP therapy
February 12, 2009
Cequent Pharmaceuticals this week unveiled non-human primate data demonstrating the safety and gene-silencing ability of its lead drug candidate, a treatment for familial adenomatous polyposis dubbed CEQ501, in what the company is calling the first proof of activity of an oral RNAi drug.
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.